Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes

Trial Profile

Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2014

At a glance

  • Drugs Sarpogrelate (Primary)
  • Indications Diabetic nephropathies
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SONATA
  • Sponsors Yuhan
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Aug 2014 Last checked against ClinicalTrials.gov record.
    • 09 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top